Canaccord lowered the firm’s price target on Rani Therapeutics to $21 from $26 and keeps a Buy rating on the shares. The firm updated its model following the company’s update on its strategic pipeline prioritization as they recently announced the discontinuation of one clinical program and the pause of two additional programs.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on RANI:
- Rani Therapeutics announces development of RT-101 cancelled, 25% workforce cut
- Rani Therapeutics sees Q3 net loss $17M -$19M
- Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
- Rani Therapeutics sees Q3 net loss $17M-$19M vs $16.2M last year
- Rani Therapeutics announces preclinical data on RaniPill platform
